Acadia Pharmaceuticals CEO Catherine Owen Adams is focused on executing near-term growth and building out a pipeline to continue the momentum the company has built in the past year. Owen Adams joined Acadia in September after a lengthy career in big pharma, including most recently overseeing Bristol Myers Squibb’s US business.
Acadia’s New CEO Outlines Growth Strategy
Continuing to grow Nuplazid and Daybue are top priorities along with pipeline and business development, Catherine Owen Adams told Scrip.
More from Strategy
More from Therapy Areas
• By
After a long wait for patients, Vykat has become the first drug approved for Prader-Willi syndrome symptoms, opening the market up for Soleno and future challengers.
• By
With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.
• By
J&J is confident that its bispecific antibody/kinase inhibitor combo’s overall survival win over AstraZeneca’s single-agent pill will shift the standard of care.